Press release

Business Wire2 weeks ago

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

VIENNA–(BUSINESS WIRE)–#AOPHealth—AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers.…
Read More »
Press Release

Cision PR Newswire2 weeks ago
0

The 4th China International Supply Chain Expo Set for Beijing in June 2026

Sustained Worldwide Outreach Drives Greater Collaboration Opportunities BEIJING, Dec. 7, 2025 /PRNewswire/ — The 4th China International Supply Chain Expo (“CISCE,”…
Read More »
Business Wire2 weeks ago

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and…
Read More »
Business Wire2 weeks ago

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of…
Read More »
Press Release

Cision PR Newswire2 weeks ago
0

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly,…
Read More »
Cision PR Newswire2 weeks ago
0

Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting

Anti-CD19 panCARTM program (ORN-252) demonstrated robust B cell depletion with significant reduction in anti-dsDNA titers in humanized lupus model Anti-BCMA…
Read More »
Business Wire2 weeks ago

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

– Benefits Seen Regardless of Eligibility for Previous Standard of Care of High-Dose Chemotherapy and Stem Cell Transplant for Second-Line…
Read More »
Business Wire2 weeks ago

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clinically meaningful…
Read More »
Business Wire2 weeks ago

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed…
Read More »
Cision PR Newswire2 weeks ago
0

Washable Area Rugs (2025): Rugs Direct Named Top Choice for Practical & Stylish Home Decor by Expert Consumers

NEW YORK, Dec. 7, 2025 /PRNewswire/ — Expert Consumers has named Rugs Direct the top choice for washable area rugs in…
Read More »

Previous page Next page